United States securities and exchange commission logo

                           February 8, 2022

       Eric A. Adams
       President and Chief Executive Officer
       InMed Pharmaceuticals Inc.
       Suite 310     815 West Hastings Street
       Vancouver, British Columbia V6C 1B4

                                                        Re: InMed
Pharmaceuticals Inc.
Statement on Form S-3
                                                            Filed February 4,
                                                            File No. 333-262532

       Dear Mr. Adams:

              This is to advise you that we have not reviewed and will not
review your registration

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Gary
Guttenberg at (202) 551-6477 with any questions.


                           Division of Corporation Finance

                           Office of Life Sciences
       cc:                                              Brian Fenske